CORONA Remedies Limited
HDFC Mutual Fund entered Corona Remedies with 25,06,683 shares, acquiring a 4.10% stake worth ₹514.88 Cr at ₹2054.10 apiece. HDFC Mutual Fund was the largest buyer in a June 17, 2026, block deal where Sepia Investments and Anchor Partners sold shares worth approximately ₹777 crore in Corona Remedies.
Corona Remedies Limited, founded in 2004 and headquartered in Ahmedabad, is a pharmaceutical company manufacturing and distributing medicines across women's healthcare, cardiology, pain management, and urology. The company operates two manufacturing facilities in Gujarat and Himachal Pradesh, holds EU-GMP and WHO certifications, and maintains market leadership positions in multiple therapeutic segments including rank #5 in women's healthcare and pain management.
One of India's oldest and most trusted AMCs with over Rs 7.5 lakh crore in AUM. Founded in 1999 as a joint venture between HDFC Bank and Standard Life. MD and CEO Navneet Munot, formerly CIO of SBI MF, has reinforced the quality and compounding philosophy across equity schemes. HDFC Flexi Cap Fund and HDFC Mid-Cap Opportunities Fund are among the largest actively managed equity schemes in India.